Take­da builds ar­se­nal for im­muno-on­col­o­gy re­search, cre­ates cell ther­a­py group

Take­da’s pres­ence in can­cer — for­ti­fied by its $5.2 bil­lion Ari­ad buy­out — is grow­ing, as it an­nounced a range of agree­ments in im­muno-on­col­o­gy and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.